Biogen (BIIB) stock edged higher early Wednesday after the biotech company reported $4.05 in adjusted earnings per share and fourth-quarter sales of $2.54 billion.
Analysts polled by FactSet expected Biogen to earn $3.48 per share on $2.44 billion in sales.
In the year-earlier period, Biogen earnings were $3.39 a share and the company reported $2.73 billion in sales.
For the year, Biogen predicted a decline in sales in the mid-single digits and adjusted earnings of $15-$16 per share. The company projected “modest in-market revenue for (Alzheimer’s treatment) Leqembi in 2023 with commercialization expenses exceeding revenue.”
Biogen stock analysts projected earnings of $15.80 a share and $9.37 billion in sales.
In premarket action on the stock market today, Biogen stock inched 0.1% ahead, trading near 289.50.
More to follow.
Follow Allison Gatlin on Twitter at @IBD_AGatlin.
YOU MAY ALSO LIKE:
InMode Jumps Despite Mixed 2023 Outlook, But Uncertainty Continues For Medpace
Zoetis Fetches A Quarterly Beat And Shares Surge To A Six-Month High
Looking For The Next Big Stock Market Winners? Start With These 3 Steps
Learn How To Time The Market With IBD’s ETF Market Strategy
Profit From Short-Term Trends With SwingTrader
#Biogen #Expects #Alzheimers #Drug #Leqembi #Face #Key #Headwind